|
|
News Breaks | | | | September 10, 2012 | | 07:09 EDT |  | CBLI | Cleveland BioLabs in FDA agreement on pivotal animal efficacy study for CBLB502
Cleveland BioLabs announced the receipt of an Advice Letter from the U.S. FDA indicating agreement with proposed pivotal animal efficacy studies for the development of CBLB502, or Entolimod, as a radiation countermeasure. The FDA also accepted the Company's recently concluded Good Laboratory Practice non-human primate, or NHP, study as part of the pivotal program. | |
|
News For CBLI From The Last 14 Days Check below for free stories on CBLI the last two weeks. |
|
|
| There are no results for CBLI |
|
|
|
|
|
|
